Mylan (VRTS) Wins Summary Judgment in EpiPen Litigation Brought by Sanofi (SNY)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Pinterest CFO resigns, interim replacement named
Mylan Wins Summary Judgment in EpiPen® Litigation Brought by Sanofi
December 18, 2020 12:21 PM ESTPITTSBURGH, Dec. 18, 2020 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that the U.S. District Court for the District of Kansas entered summary judgment in Mylan's favor in the lawsuit brought against it by Sanofi related to its EpiPen® products.
Viatris is extremely pleased with this significant action by the Court as it rejects Sanofi's baseless attempts to argue that Mylan used anticompetitive practices to market EpiPen and goes a long way in supporting the Company's commitment to vigorously defend itself against unfounded claims.
For the past three years,... More
